ProQuad

RSS

measles, mumps, rubella and varicella vaccine (live)

Authorised
This medicine is authorised for use in the European Union.

Overview

ProQuad is a vaccine against measles, mumps, rubella, and varicella (chickenpox).

ProQuad is given to children from 12 months of age to help protect them against measles, mumps, rubella, and chickenpox. ProQuad may also be given to children from 9 months of age in certain situations, for example as part of a national vaccination programme, during an outbreak or for travel to a region where measles is common.

This EPAR was last updated on 12/05/2022

Authorisation details

Product details
Name
ProQuad
Agency product number
EMEA/H/C/000622
Active substance
virus, live attenuated, measles, virus, live attenuated, mumps, virus, live attenuated, rubella, virus, live attenuated, varicella
International non-proprietary name (INN) or common name
measles, mumps, rubella and varicella vaccine (live)
Therapeutic area (MeSH)
  • Chickenpox
  • Rubella
  • Measles
  • Mumps
  • Immunization
Anatomical therapeutic chemical (ATC) code
J07BD54
Publication details
Marketing-authorisation holder
Merck Sharp & Dohme B.V.
Revision
30
Date of issue of marketing authorisation valid throughout the European Union
05/04/2006
Contact address

Waarderweg 39
2031 BN Haarlem
NETHERLANDS

Product information

13/04/2022 ProQuad - EMEA/H/C/000622 - T/0156

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Vaccines

Therapeutic indication

ProQuad is indicated for simultaneous vaccination against measles, mumps, rubella and varicella in individuals from 12 months of age.

ProQuad can be administered to individuals from 9 months of age under special circumstances (e.g., to conform with national vaccination schedules, outbreak situations, or travel to a region with high prevalence of measles.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating